 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today provided a corporate update and reported fourth quarter and full year financial results for the periods ended December 31, 2020. 